MedDataX Logo

Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate

NCT ID: NCT06730516

Last Updated: 2024-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-24

Study Completion Date

2024-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to evaluate the effects of topical Latanoprost 0.005 % versus Brimionidin tartrate 0.2% on perfusion of optic nerve head This prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral primary open angle glaucoma equally divided into two groups with 28 patients in each group

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study aimed to evaluate the effects of topical Latanoprost 0.005 % versus Brimionidin tartrate 0.2% on perfusion of optic nerve head This prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral POAG equally divided into two groups with 28 patients in each group. The whole VD was increased and also increased in all four nasal, temporal, superior, and inferior quadrants around optic disc from the initial vessel density before treatment (p\<0.001) in both groups significantly with superior improvement in group (1) compared to group (2) that was statistically significant

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Latanoprost Brimonidine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral primary open angle glaucoma equally divided into two groups with 28 patients in each group. Nine patients, five in group (1) and four in group (2) were excluded due to poor quality OCTA images or non-compliance). Group (1) included 23 patients (46 eyes) treated with Latanoprost 0.005 % while 24 patients (48 eyes) received treatment with Brimonidin tartrate 0.2% in group (2).
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Latanoprost (Xalatan)

Group (1) included 23 patients (46 eyes) treated with Latanoprost 0.005 %

Group Type EXPERIMENTAL

Latanoprost (Xalatan)

Intervention Type DRUG

latanoprost 0.005

Brimonidine 0.2%

24 patients (48 eyes) received treatment with Brimonidin tartrate 0.2% in group (2)

Group Type EXPERIMENTAL

Brimonidine 0.2 %

Intervention Type DRUG

Brimonidine0.2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Latanoprost (Xalatan)

latanoprost 0.005

Intervention Type DRUG

Brimonidine 0.2 %

Brimonidine0.2

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age more than 18 years newly diagnosed naive patients with POAG

Exclusion Criteria

* optic nerve lesions other than glaucomatous changes patients with previous glaucoma surgery
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zagazig University

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yasmine A Deiaeldin, MD

Role: STUDY_DIRECTOR

Zagazig University

Hani elbialy, MD

Role: STUDY_DIRECTOR

Zagazig University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zagazig University

Zagazig, Sharqia Province, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Zagazig University

Identifier Type: REGISTRY

Identifier Source: secondary_id

#454/25-June-2024.

Identifier Type: -

Identifier Source: org_study_id